2MEYERS A S. Orphan Drugs: the current situation in the United States, Europe, and Asia[J ]. Drug Inf J, 1997,31 ( 1 ) : 101.
3MEYERS A S. History of the American Orphan Drug Acy[R].International conference of rare disease and orphan drugs. Spain,2000.
4KOSAKU UCHIDA. Orphan drugs in Japan [ J ]. Drug Inf J,1996,30( 1 ) : 171.
5MAKOTO SHIRAGAMI, KIYOHITO NAKAI. Development of orphan drugs in Japan: Characteristics of orphan drugs developed in Japan[J ]. Drug Inf J, 2000,34(2) : 839.
6HAFTNER M E. Orphan drug development - International program and study design issues[J ]. Drug Inf J, 1998,32 (1):93 - 99.
7TROUILLER P, REY J L, BOUSCHARAIN P. Pharmaceutical development concerning diseases predominating in tropical regions: the concept of indigent drugs[ J ]. Ann Pharm Fr, 2000,58(1):43.
85.21 Code of Federal Regulations(CFR) Part 316. Orphan Drug Regulations: Final Rule[S]. Federal Register, 1992.
9SCOTT D L, MB A, ETSUKO USUI. Orphan drug programs/policies in Australia, Japan, and Canada[J ]. Drug Inf J, 2001,35(1):1.
10Haffner ME.Orphan drug development-International program and study design issues.Drug Inf J,1998,32:93-99.
5Haffner ME.Rare diseases and orphan drugs-the US expe-rience[J].Phamaceuticals Policy and Law,2001(3):37.
6FDA.Orphan drug act[EB/OL].(2011-10-19)[2012-02-09].http://www.fda.gov/RegulatoryInformation/Legislati-on/FederalFoodDrugandCosmeticActFDCAct/Significant-AmendmentstotheFDCAct/OrphanDrugAct/default.htm.
7US House of Representives.Orphan drugs[EB/OL].[2012-02-28].http://waxman.house.gov/orphan-drugs.
8Whitten JL.Hearings of the committee on appropriations house for98th congress:2nd session[C].Washington:U.S.Government Printing Office,1984.
9Senate of the USA.Congress record-senate[C].Washing-ton:Senate of the USA,1984.
10HHS.The orphan drug act implementation and impact[EB/OL].(2001-05-01)[2012-03-14].http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf.
